Artiva Biotherapeutics, Inc. 4

Artiva Biotherapeutics’ President & Head of R&D, Miralles Gines Diego, was granted 45,000 RSUs and options for 135,000 shares at $10.79 on September 9, 2026.

On September 9, 2026, Miralles Gines Diego, President & Head of R&D of Artiva Biotherapeutics, Inc., received an equity compensation package consisting of 45,000 shares of common stock in the form of restricted stock units and an employee stock option to purchase 135,000 shares at an exercise price of $10.79 per share, with the option vesting in equal monthly installments over four years beginning September 8, 2026. Following these awards, his direct beneficial ownership increased to 122,500 shares of common stock and 135,000 stock options, representing a sizable, routine incentive grant under the issuer’s 2024 Equity Incentive Plan. As no market price was provided, transaction and post-transaction values are estimated using the $10.79 option exercise price as a proxy for the underlying share value.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-389514

Alert Tier

6